1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


  
    













































































































    Are Linear Measurements of the Nucleus Basalis of Meynert Suitable as a Diagnostic Biomarker in Mild Cognitive Impairment and Alzheimer Disease? | American Journal of Neuroradiology  
    



















    































    
  
  




    
    

  

      


    

      

  
  
  

    

  

    

  

                
    

      

  

    

  
      
  
  

    


Advertisement



  



  


  
  



  



    

  


  


  


  
  
  
  
  
  

  	      


    
      

    
  
    
        
    

  

    
                        

  

                
    

      

	  

		
		

			

			  

  
      
  
  

    

  
  
      
Research ArticleAdult Brain

  
      

  
      
Are Linear Measurements of the Nucleus Basalis of Meynert Suitable as a Diagnostic Biomarker in Mild Cognitive Impairment and Alzheimer Disease?
  
    	
K.D. Jethwa, P. Dhillon, D. Meng, D.P. Auer and for the Alzheimer’s Disease Neuroimaging Initiative

  
    	
American Journal of Neuroradiology December 2019,  40 (12) 2039-2044; DOI: https://doi.org/10.3174/ajnr.A6313 

  
  
  



  


  
  



			

		

	
	
 	
	  
  

		
		

			

			  

  
      
  
  

    
  


  
  



  
      
  
  

    

  

    

  
      
  
  

    
References
  1. 1.↵
    What is dementia? Factsheet 400LP January 2017. https://www.alzheimers.org.uk/Download/Downloads/Id/3416/What_Is_Dementia.pdf. Accessed May 3, 2017
  2. 2.↵
    1. Esiri  MM, 
    2. Morris  JH.
     The Neuropathology of Dementia. Cambridge: Cambridge University Press; 2009
  3. 3.↵
    1. Selkoe  DJ.
     Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 2001;81:741–66 doi:10.1152/physrev.2001.81.2.741 pmid:11274343
    CrossRefPubMedWeb of Science
  4. 4.↵
    1. Braak  H, 
    2. Alafuzoff  I, 
    3. Arzberger  T, et al
    . Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006;112:389–404 doi:10.1007/s00401-006-0127-z pmid:16906426
    CrossRefPubMedWeb of Science
  5. 5.↵
    1. Mesulam  MM.
     Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer’s disease. J Comp Neurol 2013;521:4124–44 doi:10.1002/cne.23415 pmid:23852922
    CrossRefPubMed
  6. 6.↵
    1. Liu  AK, 
    2. Chang  RC, 
    3. Pearce  RK, et al
    . Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer’s and Parkinson’s disease. Acta Neuropathol 2015;129:527–40 doi:10.1007/s00401-015-1392-5 pmid:25633602
    CrossRefPubMed
  7. 7.↵
    1. Sassin  I, 
    2. Schultz  C, 
    3. Thal  DR, et al
    . Evolution of Alzheimer’s disease-related cytoskeletal changes in the basal nucleus of Meynert. Acta Neuropathol 2000;100:259–69 doi:10.1007/s004019900178 pmid:10965795
    CrossRefPubMed
  8. 8.↵
    1. Insausti  R, 
    2. Juottonen  K, 
    3. Soininen  H, et al
    . MR volumetric analysis of the human entorhinal, perirhinal, and temporopolar cortices. AJNR Am J Neuroradiol 1998;19:659–71 pmid:9576651
    Abstract
  9. 9.↵
    1. Teipel  SJ, 
    2. Flatz  WH, 
    3. Heinsen  H, et al
    . Measurement of basal forebrain atrophy in Alzheimer’s disease using MRI. Brain 2005;128:2626–44 doi:10.1093/brain/awh589 pmid:16014654
    CrossRefPubMedWeb of Science
  10. 10.↵
    1. Grothe  M, 
    2. Heinsen  H, 
    3. Teipel  SJ.
     Atrophy of the cholinergic basal forebrain over the adult age range and in early stages of Alzheimer’s disease. Biol Psychiatry 2012;71:805–13 doi:10.1016/j.biopsych.2011.06.019 pmid:21816388
    CrossRefPubMedWeb of Science
  11. 11.↵
    1. Grothe  MJ, 
    2. Ewers  M, 
    3. Krause  B, et al
    . Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects. Alzheimers Dement 2014;10:S344–53 doi:10.1016/j.jalz.2013.09.011 pmid:24418052
    CrossRefPubMed
  12. 12.↵
    1. Förstl  H, 
    2. Levy  R, 
    3. Burns  A, et al
    . Disproportionate loss of noradrenergic and cholinergic neurons as cause of depression in Alzheimer’s disease: a hypothesis. Pharmacopsychiatry 1994;27:11–15 doi:10.1055/s-2007-1014267 pmid:8159776
    CrossRefPubMed
  13. 13.↵
    1. Bottini  G, 
    2. Berlingeri  M, 
    3. Basilico  S, et al
    . Good or bad responder? Behavioural and neuroanatomical markers of clinical response to donepezil in dementia. Behav Neurol 2012;25:61–72 pmid:22530263
    PubMed
  14. 14.↵
    1. Hanyu  H, 
    2. Tanaka  Y, 
    3. Sakurai  H, et al
    . Atrophy of the substantia innominata on magnetic resonance imaging and response to donepezil treatment in Alzheimer’s disease. Neurosci Lett 2002;319:33–36 doi:10.1016/S0304-3940(01)02507-1 pmid:11814647
    CrossRefPubMed
  15. 15.↵
    1. Kanetaka  H, 
    2. Hanyu  H, 
    3. Hirao  K, et al
    . Prediction of response to donepezil in Alzheimer’s disease: combined MRI analysis of the substantia innominata and SPECT measurement of cerebral perfusion. Nucl Med Commun 2008;29:568–73 doi:10.1097/MNM.0b013e3282f5e5f4 pmid:18458605
    CrossRefPubMed
  16. 16.↵
    1. Meng  D, 
    2. Li  X, 
    3. Bauer  M, et al
    . Alzheimer’s disease neuroimaging, I: altered nucleus basalis connectivity predicts treatment response in mild cognitive impairment. Radiology 2018;289:775–85 doi:10.1148/radiol.2018180092 pmid:30204076
    CrossRefPubMed
  17. 17.↵
    1. Palmqvist  S, 
    2. Mattsson  N, 
    3. Hansson  O.
     Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography. Brain 2016;139:1226–36 doi:10.1093/brain/aww015 pmid:26936941
    CrossRefPubMed
  18. 18.↵
    1. Yushkevich  P, 
    2. Piven  J, 
    3. Hazlett  H, et al
    . User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage 2006;31:1116–28 doi:10.1016/j.neuroimage.2006.01.015 pmid:16545965
    CrossRefPubMedWeb of Science
  19. 19.↵
    1. Youden  WJ.
     Index for rating diagnostic tests. Cancer 1950;3:32–35 doi:10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3
    CrossRefPubMedWeb of Science
  20. 20.↵
    1. Cicchetti  D, 
    2. Sparrow  A.
     Developing criteria for establishing interrater reliability of specific items: applications to assessment of adaptive behavior. Am J Ment Defic 1981;86:127–37 pmid:7315877
    PubMedWeb of Science
  21. 21.↵
    1. Hanyu  H, 
    2. Asano  T, 
    3. Sakurai  F, et al
    . MR analysis of the substantia innominata in normal aging. AJNR Am J Neuroradiol 2002;23:27–32 pmid:11827872
    Abstract/FREE Full Text
  22. 22.↵
    1. Berger-Sweeney  J, 
    2. Heckers  S, 
    3. Mesulam  MM, et al
    . Differential effects on spatial navigation of immunotoxin-induced cholinergic lesions of the medial septal area and nucleus basalis magnocellularis. J Neurosci 1994;14:4507–19 doi:10.1523/JNEUROSCI.14-07-04507.1994 pmid:8027790
    Abstract/FREE Full Text
  23. 23.↵
    1. George  S, 
    2. Mufson  EJ, 
    3. Leurgans  S, et al
    . MRI-based volumetric measurement of the substantia innominata in amnestic MCI and mild AD. Neurobiol Aging 2011;32:1756–64 doi:10.1016/j.neurobiolaging.2009.11.006 pmid:20005600
    CrossRefPubMedWeb of Science
  24. 24.↵
    1. Dubois  B, 
    2. Feldman  HH, 
    3. Jacova  C, et al
    . Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 2014;13:614–29 doi:10.1016/S1474-4422(14)70090-0 pmid:24849862
    CrossRefPubMedWeb of Science
  25. 25.↵
    1. Grothe  MJ, 
    2. Heinsen  H, 
    3. Amaro  E, et al
    . Cognitive correlates of basal forebrain atrophy and associated cortical hypometabolism in mild cognitive impairment. Cereb Cortex 2016;26:2411–26 doi:10.1093/cercor/bhv062 pmid:25840425
    CrossRefPubMed
  26. 26.↵
    1. Buerger  K, 
    2. Alafuzoff  I, 
    3. Ewers  M, et al
    . No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer’s disease. Brain 2007;130:E82 doi:10.1093/brain/awm140 pmid:17615094
    CrossRefPubMed
  27. 27.↵
    1. Duara  R, 
    2. Loewenstein  DA, 
    3. Potter  E, et al
    . Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer disease. Neurology 2008;71:1986–92 doi:10.1212/01.wnl.0000336925.79704.9f pmid:19064880
    Abstract/FREE Full Text
  28. 28.↵
    1. Jethwa  K, 
    2. Aphiwatthanasumet  K, 
    3. Mougin  O, et al
    . Phase enhanced PSIR T1-weighted imaging improves contrast resolution of the nucleus basalis of Meynert at 7 T: a preliminary study. Magn Reson Imaging 2019;61:296–99 doi:10.1016/j.mri.2019.06.004 pmid:31202788
    CrossRefPubMed
  


  
  



  




  


  
  



  
      
  
  

    
  


  
  



  
      
  
  

     Back to top  


  
  



			

		

		
		

			

			  

  
        
In this issue

    
  
  

    
  


  
  



  
      
  
  

    

  

    

  
      
  
  

    


Advertisement



  



  


  
  



  



  


  
  



  
      
  
  

    

	  
  

		

          

            

  
      
  
  

     Print  


  
  



  
      
  
  

     Download PDF  


  
  



  
      
  
  

    
 Email Article
  


  
  



  
      
  
  

    
 Citation Tools
  


  
  



          

        

        
        

          

            



  
      
  
  

    

  

    

  
      
  
  

    

  
  
  
  
      
Are Linear Measurements of the Nucleus Basalis of Meynert Suitable as a Diagnostic Biomarker in Mild Cognitive Impairment and Alzheimer Disease?
  
    	
K.D. Jethwa, P. Dhillon, D. Meng, D.P. Auer, for the Alzheimer’s Disease Neuroimaging Initiative

  
    	
American Journal of Neuroradiology Dec 2019, 40 (12) 2039-2044; DOI: 10.3174/ajnr.A6313 

  
  
  



  


  
  



  
      
  
  

    

  
    
  
  
    
  
  
    
  


  


  
  



  
      
  
  

    
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  


  
  



  



  


  
  



  
      
  
  

    
  


  
  



          

        

	
 	
	
	


  


  
  



  
      
  
  

    
              Purchase  


  
  



  
        
Jump to section

    
  
  

    
  


  
  



  
      
  
  

    
  


  
  



			

		

	
	
 	
	
	


    

  



  

                
    

      

  

    

  
      
  
  

    


Advertisement